Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17901790 | 1.00 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2HPGDALOX15HSD17B10 | |
| SCHEMBL13359380 | 0.85 | HPGD (0.41) | ALDH1A1SMN1; SMN2HPGDALOX15HSD17B10 | |
| SCHEMBL13324904 | 0.82 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2HPGDALOX15HSD17B10 | |
| SCHEMBL10350673 | 0.82 | SMN1; SMN2 (0.48) | ALDH1A1SMN1; SMN2HPGDALOX15HSD17B10 | |
| SCHEMBL14159619 | 0.81 | SMN1; SMN2 (0.43) | ALDH1A1SMN1; SMN2HPGDALOX15HSD17B10 | |
| SCHEMBL12539736 | 0.81 | DPP4 (0.40) | ALDH1A1SMN1; SMN2HPGDL3MBTL1KMT2A | |
| SCHEMBL12199290 | 0.81 | CYP3A4 (0.47) | ALDH1A1SMN1; SMN2HPGDALOX15HSD17B10 | |
| SCHEMBL20311441 | 0.79 | CYP3A4 (0.58) | ALDH1A1SMN1; SMN2HPGDALOX15HSD17B10 | |
| SCHEMBL738198 | 0.79 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2HPGDALOX15HSD17B10 | |
| SCHEMBL18292237 | 0.78 | SMN1; SMN2 (0.47) | ALDH1A1SMN1; SMN2HPGDALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034141-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-30 | — | — | US | disclosed |
| US-12152027-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-26 | — | — | US | disclosed |
| CN-118420620-A | Heterocyclic compounds | 武田药品工业株式会社 | 2024-08-02 | — | — | CN | disclosed |
| CN-113038948-B | Heterocyclic compounds | 武田药品工业株式会社 | 2024-07-12 | — | — | CN | disclosed |
| US-11897879-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-13 | — | — | US | disclosed |
| US-20230192685-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192685-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20220089595-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-24 | — | — | US | disclosed |
| US-20220048916-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-17 | — | — | US | disclosed |
| US-11230545-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-25 | — | — | US | disclosed |
| US-20210332045-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-28 | — | — | US | disclosed |
| EP-3888652-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-10-06 | — | — | EP | disclosed |
| CN-113038948-A | Heterocyclic compounds | 武田药品工业株式会社 | 2021-06-25 | — | — | CN | disclosed |
| US-7714131-B2 | Process for the stereoselective preparation of (−)-halofenate and derivatives thereof | METABOLEX, INC. (US) | 2010-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089595-A1 | HETEROCYCLIC COMPOUND | MALT1, SQSTM1, PPM1D | ALDH1A1 1199/4885SMN1; SMN2 2190/4885HPGD 1900/4885 |
| US-20250034141-A1 | HETEROCYCLIC COMPOUND | MALT1, SQSTM1, PPM1D | ALDH1A1 1199/4885SMN1; SMN2 2190/4885HPGD 1900/4885 |
| US-11230545-B2 | Heterocyclic compound | MALT1, SQSTM1, PPM1D | ALDH1A1 1199/4885SMN1; SMN2 2190/4885HPGD 1900/4885 |
| US-20210332045-A1 | HETEROCYCLIC COMPOUND | MALT1, SQSTM1, PPM1D | ALDH1A1 1199/4885SMN1; SMN2 2190/4885HPGD 1900/4885 |
| US-20230192685-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | MALT1, CYP51A1, ME1 | ALDH1A1 1289/4885SMN1; SMN2 3090/4885HPGD 2780/4885 |
| US-12152027-B2 | Heterocyclic compound | MALT1, SQSTM1, PPM1D | ALDH1A1 1199/4885SMN1; SMN2 2190/4885HPGD 1900/4885 |
| US-20220048916-A1 | HETEROCYCLIC COMPOUND | MALT1, SQSTM1, PPM1D | ALDH1A1 1199/4885SMN1; SMN2 2190/4885HPGD 1900/4885 |
| US-11897879-B2 | Heterocyclic compound | MALT1, SQSTM1, PPM1D | ALDH1A1 1199/4885SMN1; SMN2 2190/4885HPGD 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.